A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

LINC01871 is exclusively expressed in T and NK cells and is highly induced upon CD4+ T cell activation




TekijätKalim, Ubaid Ullah; Shetty, Ankitha; Ranade, Amogh; Rundquist, Olof; Starskaia, Inna; Batkulwar, Kedar; Välikangas, Tommi; Sousa, António G. G.; Hurme, Antti; Kumpulainen, Venla; Viitala, Miro; Kosola, Sakari; Junttila, Sini; Rasool, Omid; Elo, Laura L.; Galande, Sanjeev; Lahesmaa, Riitta

KustantajaCell Press

Julkaisuvuosi2025

Lehti: iScience

Artikkelin numero113779

Vuosikerta28

Numero11

eISSN2589-0042

DOIhttps://doi.org/10.1016/j.isci.2025.113779

Julkaisun avoimuus kirjaamishetkelläAvoimesti saatavilla

Julkaisukanavan avoimuus Kokonaan avoin julkaisukanava

Verkko-osoitehttps://doi.org/10.1016/j.isci.2025.113779

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/505586490


Tiivistelmä
Long intergenic noncoding RNAs (lincRNAs) regulate biological processes in health and disease. Recent findings highlight the importance of lincRNAs in regulating T cell development and function. Here, we identified a lincRNA, LINC01871, which is highly induced upon CD4+ T cell activation and is predominantly located in the cytoplasm. The anti-inflammatory cytokine TGF-β was found to suppress its expression. Silencing LINC01871 led to a modest decrease in IL-2 secretion. Notably, LINC01871 expression was highly specific to NK cells and T cells in several cross-tissue single cell RNA-seq atlases. These data suggest that LINC01871 is specifically expressed in T and NK cells and may contribute to T cell-mediated immunity in humans.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
R.L. is supported by Research Council of Finland grants 250114, 292335, 294337, 292482, 319280, 329277, 331793, 335435, and 31444; Breakthrough T1D Foundation grant; the Novo Nordisk Foundation grant NNF19OC0057218; Jane and Aatos Erkko Foundation grant; and the Finnish Cancer Foundation grant. L.L.E. is supported by European Research Council ERC 677943, European Union’s Horizon 2020 research and innovation program 955321; and Research Council of Finland grants 310561, 314443, 329278, 335434, 335611, and 341342. R.L. and L.L.E. were supported by the Sigrid Jusélius Foundation, Turku Graduate School University of Turku, Åbo Akademi University InFLAMES Flagship Program of the Research Council of Finland 337530, Biocenter Finland, and ELIXIR Finland. AGGS was supported by the European Union’s Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie grant agreement no.: 955321. O Rundquist. was supported by the Finnish Cultural Foundation and the Sakari Alhopuro Foundation grants, K.B. was supported by the Finnish Cultural Foundation grant.


Last updated on 2025-28-11 at 15:51